Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

FDA Releases Guidance on COVID-19 CGMP Considerations for Drug Manufacturers

June 22, 2020, Covington Alert

Drug manufacturers have responded to the COVID-19 pandemic by adopting critical measures to ensure continuity in their operations—continuity that is vital to safeguarding the global drug supply. In doing so, they have faced unprecedented challenges with regard to ensuring the health of their employees, preventing COVID-19 transmission at their facilities, and mitigating associated risks to product safety and quality. In light of these challenges, the U.S. Food and Drug Administration (FDA) released a guidance document on June 19, 2020, to advise manufacturers of human and animal drug and biological products on how to manage the unique risks associated with COVID-19 infection in employees.

Share this article: